Skip to main content
Erschienen in: Tumor Biology 7/2015

01.07.2015 | Research Article

MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration

verfasst von: Guo-qing Song, Yi Zhao

Erschienen in: Tumor Biology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

The non-coding microRNAs (miRNAs) have tissue- and disease-specific expression patterns. Dysregulation of miRNAs has been associated with initiation and progression of oncogenesis in humans. The abnormal expression of CDC25B phosphatases detected in a number of tumors implies that their dysregulation is involved in malignant transformation. Using miRNA target prediction software, we found that miR-211 could target the 3′UTR sequence of CDC25B. To shed light on their roles of miR-211 in breast cancer, the expression of miR-211 was examined by real-time RT-PCR in breast cancer and normal tissues. MiR-211 is significantly downregulated in breast cancer. MiR-211 re-expression suppressed cell growth, cell cycle, migration, and invasion in triple-negative breast cancer (TNBC) cell line MDA-MB231. Luciferase expression from a reporter vector containing the CDC25B −3′UTR was decreased when this construct was transfected with miR-211. The over-expression of miR-211 suppressed the endogenous CDC25B protein level in TNBC cells. For the first time, we demonstrate that miRNA-211 is a direct negative regulator of CDC25B expression in TNBC cells, alters other related target proteins CCNB1 and FOXM1, and then inhibits breast cancer cells growth, migration, and invasion and lead G2/M arrest. The transcriptional loss of miR-211 and the resultant increase in CDC25B expression facilitate increased genomic instability at an early stage of tumor development.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Zurück zum Zitat Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.CrossRefPubMed Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.CrossRefPubMed
3.
4.
Zurück zum Zitat De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (tnbc): current options and future perspectives. Cancer Treat Rev. 2010;36 Suppl 3:S80–6.CrossRefPubMed De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (tnbc): current options and future perspectives. Cancer Treat Rev. 2010;36 Suppl 3:S80–6.CrossRefPubMed
6.
Zurück zum Zitat Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed
10.
Zurück zum Zitat Luo EC, Chang YC, Sher YP, Huang WY, Chuang LL, Chiu YC, et al. Microrna-769-3p down-regulates ndrg1 and enhances apoptosis in mcf-7 cells during reoxygenation. Sci Rep. 2014;4:5908.PubMedPubMedCentral Luo EC, Chang YC, Sher YP, Huang WY, Chuang LL, Chiu YC, et al. Microrna-769-3p down-regulates ndrg1 and enhances apoptosis in mcf-7 cells during reoxygenation. Sci Rep. 2014;4:5908.PubMedPubMedCentral
11.
Zurück zum Zitat Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014;6:384–90.PubMedPubMedCentral Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014;6:384–90.PubMedPubMedCentral
12.
Zurück zum Zitat Boutros R, Dozier C, Ducommun B. The when and wheres of cdc25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed Boutros R, Dozier C, Ducommun B. The when and wheres of cdc25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed
13.
Zurück zum Zitat Boutros R, Lobjois V, Ducommun B. Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed Boutros R, Lobjois V, Ducommun B. Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed
14.
Zurück zum Zitat Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B. Cdc25-dependent activation of cyclin a/cdk2 is blocked in g2 phase arrested cells independently of atm/atr. Oncogene. 2001;20:921–32.CrossRefPubMed Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B. Cdc25-dependent activation of cyclin a/cdk2 is blocked in g2 phase arrested cells independently of atm/atr. Oncogene. 2001;20:921–32.CrossRefPubMed
15.
Zurück zum Zitat Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25b phosphatase in mitosis triggers centrosomal microtubule nucleation in hela cells. J Cell Sci. 1996;109(Pt 5):1081–93.PubMed Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25b phosphatase in mitosis triggers centrosomal microtubule nucleation in hela cells. J Cell Sci. 1996;109(Pt 5):1081–93.PubMed
16.
Zurück zum Zitat Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25b and cdc25c differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999;146:573–84.CrossRefPubMedPubMedCentral Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25b and cdc25c differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999;146:573–84.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of cdc25b functions to coordinate mitotic events. Cell Cycle. 2006;5:2543–7.CrossRefPubMed Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of cdc25b functions to coordinate mitotic events. Cell Cycle. 2006;5:2543–7.CrossRefPubMed
18.
Zurück zum Zitat van Vugt MA, Bras A, Medema RH. Polo-like kinase-1 controls recovery from a g2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15:799–811.CrossRefPubMed van Vugt MA, Bras A, Medema RH. Polo-like kinase-1 controls recovery from a g2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15:799–811.CrossRefPubMed
19.
Zurück zum Zitat Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C. Doxorubicin promotes transcriptional upregulation of cdc25b in cancer cells by releasing sp1 from the promoter. Oncogene. 2013;32:5123–8.CrossRefPubMed Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C. Doxorubicin promotes transcriptional upregulation of cdc25b in cancer cells by releasing sp1 from the promoter. Oncogene. 2013;32:5123–8.CrossRefPubMed
20.
Zurück zum Zitat Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, et al. Rsk promotes g2/m transition through activating phosphorylation of cdc25a and cdc25b. Oncogene. 2014;33:2385–94.CrossRefPubMed Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, et al. Rsk promotes g2/m transition through activating phosphorylation of cdc25a and cdc25b. Oncogene. 2014;33:2385–94.CrossRefPubMed
21.
Zurück zum Zitat Lyons J, Bastian BC, McCormick F. Mc1r and camp signaling inhibit cdc25b activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013;110:13845–50.CrossRefPubMedPubMedCentral Lyons J, Bastian BC, McCormick F. Mc1r and camp signaling inhibit cdc25b activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013;110:13845–50.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. Microrna-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting cdc25b. Lab Invest. 2011;91:1472–9.CrossRefPubMed Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. Microrna-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting cdc25b. Lab Invest. 2011;91:1472–9.CrossRefPubMed
23.
25.
27.
Zurück zum Zitat Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefPubMed Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefPubMed
28.
Zurück zum Zitat Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of mitf-induced microrna-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.CrossRefPubMedPubMedCentral Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of mitf-induced microrna-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y, et al. Microrna-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor chd5. PLoS One. 2012;7:e29750.CrossRefPubMedPubMedCentral Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y, et al. Microrna-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor chd5. PLoS One. 2012;7:e29750.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of microrna-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39:665–72.PubMed Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of microrna-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39:665–72.PubMed
31.
Zurück zum Zitat Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–60.CrossRefPubMed Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–60.CrossRefPubMed
32.
Zurück zum Zitat Zhang Z, Zhang G, Kong C. High expression of cdc25b and low expression of 14-3-3sigma is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol. 2014;35:2503–12.CrossRefPubMed Zhang Z, Zhang G, Kong C. High expression of cdc25b and low expression of 14-3-3sigma is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol. 2014;35:2503–12.CrossRefPubMed
33.
Zurück zum Zitat Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of cdc25b in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev. 2012;13:931–5.CrossRefPubMed Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of cdc25b in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev. 2012;13:931–5.CrossRefPubMed
34.
35.
Zurück zum Zitat Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. Mir-379 regulates cyclin b1 expression and is decreased in breast cancer. PLoS One. 2013;8:e68753.CrossRefPubMedPubMedCentral Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. Mir-379 regulates cyclin b1 expression and is decreased in breast cancer. PLoS One. 2013;8:e68753.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C. Grk2 negatively regulates igf-1r signaling pathway and cyclins’ expression in hepg2 cells. J Cell Physiol. 2013;228:1897–901.CrossRefPubMed Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C. Grk2 negatively regulates igf-1r signaling pathway and cyclins’ expression in hepg2 cells. J Cell Physiol. 2013;228:1897–901.CrossRefPubMed
38.
Zurück zum Zitat Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, et al. Foxm1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012;114:755–62.CrossRefPubMed Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, et al. Foxm1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012;114:755–62.CrossRefPubMed
39.
Zurück zum Zitat Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, et al. Foxm1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 2010;122:337–46.CrossRefPubMed Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, et al. Foxm1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 2010;122:337–46.CrossRefPubMed
Metadaten
Titel
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration
verfasst von
Guo-qing Song
Yi Zhao
Publikationsdatum
01.07.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3151-6

Weitere Artikel der Ausgabe 7/2015

Tumor Biology 7/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.